Insulin Degludec: Uses, Safety, and Glargine Comparison

Insulin degludec is an ultra-long-acting basal insulin with a half-life of roughly 25 hours, giving it the flattest and most stable glucose-lowering profile among currently available basal insulins. Approved for adults and children with type 1 and type 2 diabetes, it works through a unique molecular mechanism that creates a slow-release depot under the skin after each injection. What makes it genuinely different from older basal insulins is not just duration but predictability, and that distinction carries real consequences for hypoglycemia risk, dosing schedules, and day-to-day life with diabetes.

How It Works Under the Skin

In the pen cartridge, insulin degludec molecules sit as pairs of hexamers (dihexamers) held together by zinc and a preservative called phenol. After you inject, the phenol disperses into surrounding tissue. Without phenol, the dihexamers snap together into long, soluble chains made up of hundreds of hexamers. These chains form a depot in the subcutaneous tissue that gradually releases individual insulin molecules into the bloodstream as zinc slowly dissipates.¹ Biophysical studies have confirmed that these multihexamer chains reach an average molecular mass orders of magnitude larger than the starting dihexamers, and the assembly is entirely driven by the change in local environment after injection.²

This depot acts like a buffer. Because monomers peel off the chains at a slow, consistent rate, the insulin entering your blood does not arrive in a spike the way shorter-acting insulins do. The result is a terminal half-life of about 25 hours and, at steady state, an exceptionally flat concentration curve with a lower peak-to-trough ratio than other basal insulins.³ In practical terms, once you have been dosing daily for a few days and reach steady state, the amount of active insulin in your body at 3 a.m. is very close to what it is at 3 p.m.

Day-to-Day Variability Compared with Glargine

The flatness of the profile matters less than its consistency from one day to the next. In a clamp study comparing degludec with insulin glargine U100 at steady state in people with type 1 diabetes, the day-to-day variability in glucose-lowering effect was about four times lower with degludec. The coefficient of variation for total metabolic effect over 24 hours was 20% with degludec versus 82% with glargine.⁴ A cross-study comparison later confirmed that this variability advantage also held against glargine U300, though the gap was narrower.⁵

Why does variability matter so much? If your basal insulin delivers more activity on Monday than it does on Tuesday for the same dose, your blood sugar swings in ways you cannot easily correct with food or bolus insulin. High variability is one reason people on basal insulin experience unexplained lows overnight or unexplained highs the next morning despite “doing everything right.” A more predictable basal insulin reduces those mystery episodes.

Hypoglycemia Risk

Lower variability translates directly into fewer low blood sugar events, and the clinical trial data on this point is extensive. The DEVOTE trial, a large cardiovascular-outcomes study in people with type 2 diabetes at high cardiovascular risk, found that the rate of overall symptomatic hypoglycemia during the maintenance period was about 30% lower with degludec than with glargine U100. Nocturnal hypoglycemia dropped even more sharply, with a rate roughly 42% lower.⁶

A meta-analysis of the phase 3 BEGIN trials showed a consistent pattern. In people with type 2 diabetes who had never used insulin before, rates of overall confirmed hypoglycemia were about 17% lower, nocturnal episodes about 36% lower, and severe episodes dramatically lower with degludec compared with glargine. In the broader type 2 diabetes population across these trials, overall and nocturnal confirmed hypoglycemia remained significantly reduced. In type 1 diabetes, the nocturnal advantage persisted during the maintenance phase, with a roughly 25% lower rate of confirmed nocturnal episodes.⁷ The nocturnal benefit is particularly consistent across studies and populations, which makes sense given the ultra-flat overnight profile.

For people already using high doses of basal insulin, a separate meta-analysis of the BEGIN trials found a 21% lower rate of overall confirmed hypoglycemia and a 52% lower rate of nocturnal episodes with degludec.⁸ These are meaningful differences for a population that often struggles with frequent lows.

Dosing Flexibility

Because the half-life is so long and the steady-state profile so flat, degludec can tolerate wider variation in injection timing than older basal insulins. A trial in people with type 1 diabetes tested this explicitly by forcing participants to alternate between 8-hour and 40-hour gaps between doses, creating an intentionally extreme schedule. Even under those conditions, blood sugar control was no worse than with glargine given at the same time each day. The blood sugar reduction was similar across the fixed-dose degludec group, the forced-flex degludec group, and the glargine group.⁹

This flexibility is not just an academic curiosity. Shift workers, frequent travelers, people with erratic schedules, and teenagers who do not inject at the same minute every evening all benefit from a basal insulin that does not punish them for a few hours of timing drift. With glargine or detemir, injecting several hours late can leave a noticeable gap in coverage; with degludec, the long-acting depot smooths over those gaps.

Cardiovascular Safety

The DEVOTE trial enrolled over 7,600 people with type 2 diabetes who had established cardiovascular disease or were at high cardiovascular risk. Over a median follow-up of about two years, major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) occurred at similar rates: roughly 8.5% in the degludec group and 9.3% in the glargine group, with a hazard ratio of 0.91 confirming that degludec was not inferior to glargine for cardiovascular safety.¹⁰ DEVOTE also showed significantly lower rates of severe hypoglycemia with degludec, with rate ratios of 0.60 for severe and 0.47 for nocturnal severe events, reinforcing the safety advantage beyond the cardiovascular question.¹¹

A subanalysis of DEVOTE by age group found that the treatment effects on cardiovascular events, mortality, and severe hypoglycemia were consistent whether participants were 50 to 64, 65 to 74, or 75 and older. Older participants had higher baseline risks across the board, but the relative benefit of degludec over glargine for reducing severe hypoglycemia held regardless of age.¹²

How It Compares with Glargine U300

Glargine U300 (marketed as Toujeo) is the other concentrated, long-acting basal insulin competing in this space. The head-to-head CONCLUDE trial in people with type 2 diabetes already on insulin found that overall symptomatic hypoglycemia rates were not significantly different between degludec U200 and glargine U300. However, exploratory endpoints suggested lower rates of nocturnal symptomatic hypoglycemia and substantially lower rates of severe hypoglycemia with degludec.¹³ Because the primary endpoint did not reach significance, those secondary results are considered exploratory and should be interpreted cautiously.

A real-world comparative effectiveness study in insulin-naïve people with type 2 diabetes found that degludec was associated with a larger reduction in HbA1c, a 30% lower likelihood of hypoglycemia, and 27% less treatment discontinuation compared with glargine U300 over 180 days.¹⁴ Real-world data always comes with confounding risks, but the persistence finding is interesting: people stuck with degludec longer, which matters for a medication that only works if you keep taking it.

The Combination with Liraglutide

Degludec is also available in a fixed-ratio combination pen with liraglutide, a GLP-1 receptor agonist. The combination, known as IDegLira (marketed as Xultophy), pairs the basal insulin’s fasting glucose control with liraglutide’s effects on post-meal glucose, appetite, and weight. In clinical trials, IDegLira lowered HbA1c by about 1.9 percentage points, compared with roughly 1.4 for degludec alone and 1.3 for liraglutide alone. More participants reached target HbA1c levels, and crucially, the proportion hitting target without weight gain and without hypoglycemia was markedly higher with the combination than with degludec alone.¹⁵

Weight is the practical headline here. Degludec alone was associated with modest weight gain (about 1.6 kg over 26 weeks in one trial), while IDegLira produced a slight weight loss of about 0.5 kg. Over a full year, about 78% of participants on IDegLira achieved an HbA1c below 7%, versus 63% on degludec alone, and IDegLira was associated with about 37% less hypoglycemia than degludec alone.¹⁶ A separate trial designed to isolate the contribution of liraglutide found that at equivalent insulin doses, IDegLira achieved about a full percentage point more HbA1c reduction and roughly 2.7 kg more weight loss than degludec alone.¹⁷

Use in Children and Adolescents

Degludec is approved for pediatric use in many countries. A 52-week trial comparing degludec with insulin detemir in children and adolescents with type 1 diabetes found equivalent long-term HbA1c control, a significant reduction in fasting plasma glucose, and a 30% lower basal insulin dose requirement with degludec. Rates of hyperglycemia with ketosis were also significantly lower. Hypoglycemia rates overall were similar between the two insulins, though nocturnal events trended lower with degludec.¹⁸

A real-world study from India in pediatric type 1 diabetes showed a significant drop in HbA1c (from about 9.7% to 8.6%) and fasting glucose over 26 weeks after switching to degludec. In participants monitored with continuous glucose monitoring who had been on glargine, both overall and nocturnal hypoglycemia episodes dropped significantly. No cases of diabetic ketoacidosis or severe hypoglycemia occurred during the study period.¹⁹ The dosing flexibility is especially appealing for younger patients, where injection timing can be difficult to enforce consistently.²⁰

Kidney Disease, Liver Disease, and Older Adults

Pharmacokinetic studies show that degludec’s absorption and clearance are unaffected by kidney or liver problems. People with mild, moderate, or severe hepatic impairment had virtually identical drug exposure to people with normal liver function after a single dose.²¹ The same held true for people with varying degrees of renal impairment, including those on hemodialysis. Drug exposure was comparable whether the assessment period included a dialysis session or not.²² This means no dose adjustment is needed based on kidney or liver function alone, though as with any insulin, these populations still require careful glucose monitoring because their overall insulin sensitivity and metabolism may change.

In hospitalized older adults with diabetes, an observational study found degludec achieved glucose management with a low rate of hypoglycemic episodes and no cases of severe hypoglycemia.²³ For elderly patients living at home, the lower hypoglycemia risk and dosing flexibility can be practical advantages, since a caregiver or nurse who visits at slightly different times each day can still deliver a consistent insulin effect.

Pregnancy

For years, degludec lacked safety data in pregnancy. The EXPECT trial changed that. This multinational trial randomized pregnant women with type 1 diabetes to degludec or detemir (the previously recommended long-acting insulin in pregnancy). The mean last HbA1c before delivery was 6.2% with degludec and 6.3% with detemir, confirming non-inferiority. Hypoglycemia rates were similar between groups, and no additional maternal or fetal safety concerns emerged with degludec.²⁴

A smaller observational study of 22 women who had been on degludec before conceiving and continued it through pregnancy reported comparable glycemic outcomes and pregnancy outcomes to a matched group on glargine. No significant differences appeared in severe hypoglycemia, obstetrical complications, or neonatal outcomes.²⁵ The EXPECT investigators also measured degludec levels in umbilical cord blood and found no correlation between those levels and neonatal hypoglycemia, providing additional reassurance.²⁶ These data collectively suggest that women already on degludec who become pregnant do not need to switch away from it, though the decision should be made with a clinician familiar with the patient’s history.

Patient Experience and Treatment Satisfaction

Beyond clinical endpoints, degludec appears to improve how people feel about their diabetes management. A study in people with type 1 diabetes and a history of hypoglycemia found that after six months on degludec, treatment satisfaction scores improved significantly, perceived frequency of both hypoglycemia and hyperglycemia decreased, and fear of hypoglycemia dropped.²⁷ The fear-of-hypoglycemia finding is worth pausing on. Fear of lows is one of the strongest barriers to good insulin management. People who are afraid of going low tend to run their blood sugars higher than they need to, which worsens long-term outcomes. Reducing that fear through a genuinely more predictable insulin has downstream effects that clinical trials measuring HbA1c alone do not fully capture.

A real-world study of people with type 2 diabetes who started or switched to a degludec-containing regimen across six countries showed a 1.4 percentage point HbA1c improvement, a small but significant weight reduction, and lower rates of hypoglycemia compared with their previous treatment. Participants who had been on insulin before the switch also required a lower total basal dose.²⁸

Cost-Effectiveness

Degludec typically costs more per unit than glargine U100, so the cost-effectiveness question is whether the hypoglycemia reduction and improved outcomes offset that price premium. The answer seems to be yes in most modeled analyses, though it depends heavily on the population. A UK analysis estimated that degludec fell well within accepted cost-effectiveness thresholds for people with type 2 diabetes on basal insulin, with the result driven primarily by fewer severe and nocturnal hypoglycemic events. When the model was restricted to patients who had experienced at least one hypoglycemic episode per year, degludec became even more cost-effective.²⁹

A Spanish analysis found degludec was the dominant strategy (cheaper and more effective) for people with type 2 diabetes on basal-only therapy and cost-effective in basal-bolus regimens for both type 1 and type 2 diabetes.³⁰ A Swedish model similarly found degludec dominant in type 1 diabetes over a one-year horizon and cost-effective in type 2 diabetes, with long-term projections showing net savings for both diabetes types.³¹ The common thread in all these analyses is that the savings come from fewer hypoglycemic episodes and their associated emergency visits, hospitalizations, and lost work days. For someone who rarely experiences hypoglycemia on their current insulin, the economic case for switching is weaker.

The Delivery Pen

Degludec is delivered through the FlexTouch pen, which comes in two concentrations: 100 units/mL and 200 units/mL. The 200 units/mL version allows people who need high doses to inject half the volume, which can be more comfortable. Testing found that all doses delivered from the FlexTouch pen met international accuracy standards, and the pen required significantly less thumb force to push the plunger than some competing insulin pens.³² That lower force matters more than it sounds: people with arthritis or hand weakness, common in long-standing diabetes, can struggle with stiffer pens. It also matters for children or elderly patients whose grip strength may be limited.